A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

• Status: Active, not recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid tumors and lymphoma

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alexo Therapeutics, Inc.; ALX Oncology Inc.
• Treatments: Antibodies, Monoclonal; Paclitaxel; Pembrolizumab; Ramucirumab; Rituximab; Trastuzumab

Criteria

Inclusion Criteria:

• Histological or cytological diagnosis of advanced/metastatic solid tumor malignancy; or relapsed or refractory Non-Hodgkin lymphoma for whom no standard therapy is available..

• Adequate Bone Marrow Function.

• Adequate Renal & Liver Function.

• Adequate Performance Status

Exclusion Criteria:

• Patients with known symptomatic CNS metastases or lepotomeningeal disease requiring steroids.

• Previous high-dose chemotherapy requiring allogenic stem cell rescue.

• Prior treatment with a CD47 or signal regulatory protein (SIRP) alpha targeting agent.